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Background. Left ventricular thrombus (LVT) is a complication of acute myocardial infarction (AMI) due to localised haemostasis.
LVT is typically seen 3-12 days following AMI and is seldom seen within the first 24 hours. LVT increases the risk of mortality due
to systemic thromboembolism. Patients with Coronavirus Disease-19 (COVID-19) are potentially hypercoagulable and this may
promote early development of LVT. Case. A 50-year-old man with no past medical history was admitted with a severe diabetic
ketoacidosis following a 4-day history of cough and fever. The patient tested positive for COVID-19 and required intensive care
treatment for ventilation and haemofiltration. After returning to ward-based care, the patient developed chest pain and
electrocadiographic changes consistent with an acute anterior ST-elevation myocardial infarction. Emergency percutaneous
coronary intervention was performed to the left anterior descending artery. However, the patient developed diuretic-resistant
pulmonary oedema and a bedside echocardiogram revealed significant LVT despite only 4 hours of chest pain. The thrombus
was associated with the anteroseptal wall of the left ventricle which was hypokinetic but not aneurysmal. An intra-aortic balloon
pump (IABP) was inserted, but the patient developed ipsilateral lower limb ischaemia due to the formation of thrombus in the
femoral artery and irreversible cardiogenic shock from which he ultimately succumbed. Conclusion. COVID-19-positive patients
are potentially hypercoagulable, and MI in this population may precipitate LVT earlier than expected. Consideration should be
made for routine early screening of post-MI COVID-19 patients for LVT. If detected, anticoagulation may reduce the risk of
cardiovascular mortality in this high-risk group.
1. Introduction
Left ventricular thrombus (LVT) complicates up to 15% of all
acute myocardial infarction (AMI) cases [1] and 25% of
patients with anterior myocardial infarction [2]. A postin-
farction triad of hypercoagulability, left ventricular (LV)
hypokinesia or aneurysm, and local myocardial inflamma-
tion creates an area of relatively static blood which is prone
to thrombus formation.
Traditionally, LVT has been detected by transthoracic
echocardiography (TTE) with the use of contrast enhance-
ment if the LV endocardium is not clearly visualised. A serial
study using TTE found that LVT is typically detected 3-4
days following myocardial infarction (MI), with very few
cases detectable within the first 24 hours [3]. In another serial
TTE study of 105 patients, no cases of LVT were observed
within the first 11:3 ± 8 hours and the median time to the
first discovery of LVT following anterior MI was 6 days.
Cardiovascular magnetic resonance (CMR) imaging has
superseded echocardiography as the most accurate modality
for the detection of LVT [4]. Recent evidence has shown that
CMR performed 9-12 days post-MI gives the highest detec-
tion rate [5].
The incidence of LVT has fallen significantly since wide-
spread early percutaneous coronary intervention (PCI) has
been widely adopted for the management of AMI. In clinical
practice, LVT is most commonly seen in late-presenting MI
patients. In patients who present early and undergo prompt
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revascularisation, LVT is rarely observed, particularly within
the first 24 hours of AMI.
The emergence of the novel zoonotic Severe Acute
Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has
resulted in Coronavirus Disease 2019 (COVID-19) becom-
ing a major global pandemic. Although the predominant
symptoms are respiratory, cardiovascular complications have
also been described. Studies have reported that COVID-19
patients are subject to a significant derangement of haemos-
tasis, resulting in hypercoagulability as seen on whole blood
thromboelastography [6].
In this case, we describe a COVID-19 patient who suf-
fered an acute anterior myocardial infarction and had readily
detectable, established LVT on transthoracic echocardiog-
raphy, within 4 hours of presentation.
2. History of Presentation
A 50-year old man with no past medical history was admitted
to hospital by ambulance after his wife found him unrespon-
sive. On admission, the patient was confused and agitated
with a Glasgow Coma Scale (GCS) score of 11.
3. Examination
On examination, the patient had mottled legs, dry mucous
membranes, and peripheral circulatory collapse. Blood
pressure (BP) and peripheral oxygen saturations were
unrecordable.
4. Investigations
Arterial blood gas measurements revealed a blood glucose
beyond the upper limit of recordable value (despite no
history of diabetes) and ketones of 3.6mmol/L with a lac-
tic acidosis.
Notable abnormal blood tests included an acute kidney
injury (urea 41.3mmol/L, creatinine 277μmol/L, estimated
glomerular filtration rate of 21mL/min), hypernatraemia
(Na 172mmol/L), and hypercholersterolaemia (total choles-
terol 9.0mmol/L). The white cell count was normal
(9:3 × 109), but the C-reactive protein level was raised at
53mg/L and over the following 5 days increased to 374mg/L.
5. Differential Diagnosis
The patient was thought to have a new diagnosis of diabe-
tes mellitus presenting as either a diabetic ketoacidosis or
hyperosmolar hyperlycaemic state provoked by COVID-
19 infection.
6. Course of Disease and Management
The patient was initially treated with intravenous (IV) fluids,
antibiotics, and an insulin infusion until the blood glucose
reduced to acceptable levels, following which he was treated
with subcutaneous insulin. A collateral history revealed that
the patient had a 4-day history of cough and pyrexia. One
week prior to admission, two members of his household
had been unwell with COVID-19 symptoms. The patient
Figure 1: CTPA: bilateral patchy consolidation in keeping with COVID-19 with superadded aspergillosis infection causing cavitating lesions.
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tested positive for COVID-19, and despite 3 days of ward-
based treatment, his condition continued to deteriorate.
Worsening respiratory failure necessitated transfer to the
intensive care unit (ICU) for intubation and ventilation.
The circulation was supported by vasopressors and continu-
ous veno-venous haemofiltration was commenced.
(a)
(b)
Figure 2: Coronary angiogram in the PA cranial view demonstrating (a) LAD occlusion before intervention and (b) reperfusion following
implantation of a drug-eluting stent.





Figure 3: Transthoracic echocardiogram demonstrating thrombus on the mid-to-apical anteroseptal left ventricular wall in the (a)
parasternal long axis view and (b) apical 4-chamber view.
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Twelve days after admission, the patient was transferred
back to the ward. Once again, his respiratory status declined
and a computed tomography pulmonary angiogram (CTPA)
revealed patchy consolidation and cavitation (Figure 1). Two
sputum samples tested positive for aspergillus, and the
patient was treated with voriconazole.
One month after admission, the patient suddenly devel-
oped acute chest pain. An electrocardiogram (ECG) demon-
strated anterior ST-segment elevation. The patient was taken
to the cardiac catheterisation suite for an emergency coro-
nary angiogram. This demonstrated acute occlusion of the
left anterior descending (LAD) artery (Figure 2(a)) and mod-
erate bystander atheroma in the other coronary vessels. The
patient was treated with primary percutaneous coronary
intervention (PCI) to the LAD with implantation of a single
drug-eluting stent, restoring TIMI 3 flow in the vessel. How-
ever, during the procedure, the patient developed acute pul-
monary oedema with poor response to IV furosemide.
Bedside transthoracic echocardiography revealed moderately
impaired left ventricular (LV) function with the greatest
function in the basal segments. Surprisingly, LV thrombus
was noted attached to the anteroseptal LV wall, which was
hypokinetic but not aneurysmal (Figure 3).
The patient was reintubated and readmitted to the inten-
sive care unit. High-sensitive troponin I was measured at
>50,000 ng/L one day postinfarction, having been only
2540 ng/L one day earlier, indicating an acute large territory
myocardial infarction had occurred. The total plasma choles-
terol level was rechecked and was within the normal range.
The patient developed cardiogenic shock resistant to ino-
tropes, and despite insertion of an intra-aortic balloon pump
(IABP), cardiac output did not improve. Ipsilateral lower
limb ischaemia developed as a result of a hypercoagulable
state and IABP. Ultrasound of the right femoral artery con-
firmed the presence of thrombus in the vessel. Vascular sur-
geons did not feel that the patient would survive emergency
vascular surgery, and after discussions with the family, treat-
ment was withdrawn and the patient succumbed to cardio-
genic shock.
7. Discussion
This case report describes an unusual case whereby estab-
lished LVT was detected only 4 hours after the onset of acute
anterior ST-elevation MI in a patient recovering from severe
COVID-19 infection.
Studies have demonstrated that COVID-19 infection is
associated with several cardiovascular complications includ-
ing myocarditis, arrhythmias, and vascular inflammation.
Localised inflammation at the plaque level may disrupt stable
coronary atheroma and predispose to acute coronary syn-
dromes [7].
Although the patient in this case did not have a history of
angina, moderate multivessel coronary atheroma was found
on coronary angiography, indicating preexisting asymptom-
atic coronary artery disease. The presence of COVID-19
infection may have not only promoted plaque instability in
the LAD but also the development of early LVT.
Although the prevalence of LVT has fallen in the modern
era of early revascularisation, frequency of detection is likely
to increase during the COVID-19 pandemic. Firstly, patients
with MI symptoms are more likely to avoid early hospital
admission due to a fear of contracting COVID-19. Secondly,
COVID-19 infection has been associated with markedly
hypercoagulable thromboelastography profiles, increasing
the risk of early LVT formation.
Detection of LVT in COVID-19 post-MI patients is par-
amount due to the risk of systemic thromboembolism, fur-
ther increasing the risk of morbidity and mortality in this
high-risk group. International guidelines recommend antic-
oagulation if LVT is detected [8]. This case highlights that
COVID-19 patients presenting with MI are at risk of early
LVT formation and should be evaluated with early inpatient
echocardiography, with a low threshold for contrast echocar-
diography or CMR if necessary.
Additional Points
Learning Objectives. Case: a patient with COVID-19 who
developed early LV thrombus. (i) Patients with COVID-19
are potentially hypercoagulable and may form LV thrombus
far earlier than expected. (ii) Consider early inpatient imag-
ing following acute MI in COVID-19 patients with echocar-
diography or CMR if necessary.
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